Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Donanemab for Alzheimer Disease—Who Benefits and Who Is Harmed?
Jennifer J. Manly, Kacie Deters
JAMA (2023) Vol. 330, Iss. 6, pp. 510-510
Closed Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

Updates in Alzheimer's disease: from basic research to diagnosis and therapies
Enjie Liu, Yao Zhang, Jian–Zhi Wang
Translational Neurodegeneration (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 17
Anti-Amyloid Therapies for Alzheimer’s Disease and the Amyloid Cascade Hypothesis
Ernesto Fedele
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 19, pp. 14499-14499
Open Access | Times Cited: 36
Immunotherapies for Alzheimer’s disease
Todd E. Golde, Allan I. Levey
Science (2023) Vol. 382, Iss. 6676, pp. 1242-1244
Closed Access | Times Cited: 29
The path to next-generation disease-modifying immunomodulatory combination therapies in Alzheimer’s disease
Marie Sarazin, Julien Lagarde, I. Haddad, et al.
Nature Aging (2024) Vol. 4, Iss. 6, pp. 761-770
Closed Access | Times Cited: 12
“We are not invited”: Australian focus group results on how to improve ethnic diversity in trials.
Bianca Brijnath, Rachel Muoio, Peter Feldman, et al.
Journal of Clinical Epidemiology (2024) Vol. 170, pp. 111366-111366
Open Access | Times Cited: 8
Association of plasma biomarkers of Alzheimer's disease and related disorders with cognition and cognitive decline: The MYHAT population‐based study
Yingjin Zhang, Pâmela C.L. Ferreira, Erin Jacobsen, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 6, pp. 4199-4211
Open Access | Times Cited: 7
Considering challenges for the new Alzheimer's drugs: Clinical, population, and health system perspectives
Sebastian Walsh, Richard L. Merrick, Richard Milne, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 9, pp. 6639-6646
Open Access | Times Cited: 7
A Scoping Review of Alzheimers Disease Hypotheses: An Array of Uni- and Multi-Factorial Theories
Simon Duchesne, Louis‐Simon Rousseau, Florence Belzile-Marsolais, et al.
Journal of Alzheimer s Disease (2024) Vol. 99, Iss. 3, pp. 843-856
Open Access | Times Cited: 6
Potentially Modifiable Dementia Risk Factors in Canada: An Analysis of Canadian Longitudinal Study on Aging with a Multi-Country Comparison
Sung Hyun Son, Mark Speechley, Guangyong Zou, et al.
The Journal of Prevention of Alzheimer s Disease (2024)
Open Access | Times Cited: 4
What's in It for Me? Contextualizing the Potential Clinical Impacts of Lecanemab, Donanemab, and Other Anti-β-amyloid Monoclonal Antibodies in Early Alzheimer's Disease
Michelle Jin, James M. Noble
eNeuro (2024) Vol. 11, Iss. 9, pp. ENEURO.0088-24.2024
Open Access | Times Cited: 4
Variability of cognitive changes after donanemab treatment
R.A.L. Dampney
Alzheimer s & Dementia (2025) Vol. 21, Iss. 1
Open Access
Rock inhibitors in Alzheimer’s disease
Chao Zheng, Weiming Xia, Jianhua Zhang
Frontiers in Aging (2025) Vol. 6
Open Access
A mass-producible macaque model displays a durable Alzheimer-like cognitive deficit and hallmark amyloid-β/tau/neurofilament light chain pathologies
Feng He, Wenjiao Shi, Wen Liu, et al.
Journal of Alzheimer s Disease (2025)
Closed Access
pS396/pS404 (PHF1) tau vaccine outperforms pS199/pS202 (AT8) in rTg4510 tauopathy model
Jonathan Hulse, Nicole Maphis, Julianne Peabody, et al.
npj Vaccines (2025) Vol. 10, Iss. 1
Open Access
Brain metabolic imaging-based model identifies cognitive stability in prodromal Alzheimer’s disease
Jarrad Perron, Carly Scramstad, Ji Hyun Ko
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
APOE Genotype in the Era of Disease-Modifying Treatment With Monoclonal Antibodies Against Amyloid-β
Rik Ossenkoppele, Wiesje M. van der Flier
JAMA Neurology (2023) Vol. 80, Iss. 12, pp. 1269-1269
Closed Access | Times Cited: 7
Underrepresented and Underserved Populations in Neurological Research
Charles Windon, Ashley Jackson, Gloria A. Aguirre, et al.
Seminars in Neurology (2024) Vol. 44, Iss. 02, pp. 168-177
Closed Access | Times Cited: 2
Passive Anti-Amyloid Beta Immunotherapies in Alzheimer’s Disease: From Mechanisms to Therapeutic Impact
Thomas Gabriel Schreiner, Cristina Croitoru, Diana Nicoleta Hodorog, et al.
Biomedicines (2024) Vol. 12, Iss. 5, pp. 1096-1096
Open Access | Times Cited: 2
ROCK Inhibitor Fasudil Attenuates Neuroinflammation and Associated Metabolic Dysregulation in the Tau Transgenic Mouse Model of Alzheimer’s Disease
Xiaosen Ouyang, Roberto Collu, Gloria A. Benavides, et al.
Current Alzheimer Research (2024) Vol. 21, Iss. 3, pp. 183-200
Closed Access | Times Cited: 2
Challenges for emergency departments: Anti‐amyloid therapy and amyloid‐related imaging abnormalities in persons with dementia
Alexander X. Lo, Richard D. Shih, A. Sasha Rackman, et al.
Journal of the American Geriatrics Society (2024)
Open Access | Times Cited: 2
Gaps in biomedical research in frontotemporal dementia: A call for diversity and disparities focused research
Karen Nuytemans, Sanne Franzen, Iris Broce, et al.
Alzheimer s & Dementia (2024)
Open Access | Times Cited: 2
Donanemab leads to modest slowing of Alzheimer’s progression, study finds
Gareth Iacobucci
BMJ (2023), pp. p1659-p1659
Closed Access | Times Cited: 6
Prescribing anti‐amyloid immunotherapies to treat Alzheimer's disease: Fully informing patient decisions
Barry Greenberg, Cynthia A. Lemere, Lisa L. Barnes, et al.
Alzheimer s & Dementia Translational Research & Clinical Interventions (2023) Vol. 9, Iss. 4
Open Access | Times Cited: 4
2023 Year in Review and What’s Ahead at JAMA
Kirsten Bibbins‐Domingo, Annette Flanagin, Stacy Christiansen, et al.
JAMA (2024) Vol. 331, Iss. 14, pp. 1181-1181
Closed Access | Times Cited: 1
Virus-like particle (VLP)-based vaccine targeting tau phosphorylated at Ser396/Ser404 (PHF1) site outperforms phosphorylated S199/S202 (AT8) site in reducing tau pathology and restoring cognitive deficits in the rTg4510 mouse model of tauopathy
Jonathan Hulse, Nicole Maphis, Julianne Peabody, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top